Coagulation factor VIIa Recombinant Human
- Generic Name
- Coagulation factor VIIa Recombinant Human
- Brand Names
- Niastase RT, Novoseven, Sevenfact, NovoSeven
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 102786-61-8
- Unique Ingredient Identifier
- AC71R787OV
- Background
Recombinant human coagulation Factor VIIa (rFVIIa), intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues. Cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.
- Indication
For treatment of hemorrhagic complications in hemophilia A and B.
- Associated Conditions
- Bleeding, Bleeding caused by Hemophilia A, Bleeding caused by Hemophilia B, Severe Bleeding
- Associated Therapies
- -
A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan
- Conditions
- Interventions
- First Posted Date
- 2013-06-13
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 4
- Registration Number
- NCT01876745
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2013-04-12
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 15
- Registration Number
- NCT01830712
- Locations
- 🇺🇸
Novo Nordisk Clinical Trial Call Center, Princeton, New Jersey, United States
Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2012-04-27
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 9
- Registration Number
- NCT01586936
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery
- Conditions
- Interventions
- First Posted Date
- 2012-04-18
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 86
- Registration Number
- NCT01579968
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice
- Conditions
- Interventions
- First Posted Date
- 2012-04-18
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 321
- Registration Number
- NCT01579955
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography
- Conditions
- Interventions
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2016-11-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 17
- Registration Number
- NCT01561924
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom
Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding
- Conditions
- Interventions
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2016-11-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 91
- Registration Number
- NCT01561950
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Neptune, New Jersey, United States
Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment
- Conditions
- Interventions
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2016-11-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 127
- Registration Number
- NCT01561937
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Overland Park, Kansas, United States
Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 72
- Registration Number
- NCT01392547
- Locations
- 🇵🇷
Novo Nordisk Clinical Trial Call Center, San Juan, Puerto Rico
PROPACT: Retrospective Prophylaxis Patient Case Collection
- Conditions
- Interventions
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 86
- Registration Number
- NCT00882778
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Crawley, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.